Seqens North America Overview
- Year Founded
-
1995
- Status
-
Acquired/Merged
- Employees
-
150
- Latest Deal Type
-
Buyout/LBO
- Financing Rounds
-
2
- Investments
-
1
Seqens North America General Information
Description
Manufacturer of drug substances and specialty chemical products catering to pharmaceutical and medical device industries. The company offers a wide range of services, including process research and early-stage development as well as commercial production of new chemical entities and generic active pharmaceutical ingredients.
Contact Information
Website
www.pcisynthesis.comCorporate Office
- 9 Opportunity Way
- Newburyport, MA
- United States
Corporate Office
- 9 Opportunity Way
- Newburyport, MA
- United States
Seqens North America Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Seqens North America Comparisons
Industry
Financing
Details
00000
000 00
Seqens North America Competitors (9)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Bayer | Corporation | Leverkusen, Germany | 00000 | 00.00 | 000000000000 | 00.00 |
| Par Pharmaceutical Companies | Formerly PE-Backed | Ramapo, NY | 0000 | 00.000 | 0000000000. | |
| Dalton Pharma Services | Corporate Backed or Acquired | Toronto, Canada | 000 | 000000&0 | ||
| CordenPharma | Private Equity-Backed | Plankstadt, Germany | 0000 | 000000000000 | ||
| Mallinckrodt | Formerly PE-Backed | Dublin, Ireland | 0000 | 00.00 | 0000000000. |
Seqens North America Patents
Seqens North America Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-3728178-A1 | Synthesis of azelaic acid | Inactive | 22-Dec-2017 | 000000000 | |
| CA-3086530-A1 | Synthesis of azelaic acid | Pending | 22-Dec-2017 | 000000000 | |
| EP-3728178-A4 | Synthesis of azelaic acid | Inactive | 22-Dec-2017 | 000000000 | 0 |
| US-10358408-B2 | Synthesis of azelaic acid | Inactive | 22-Dec-2017 | 000000000 | 00 |
| US-20190194115-A1 | Synthesis of azelaic acid | Active | 22-Dec-2017 | C07C51/38 |
Seqens North America Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Seqens North America Acquisitions (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Borregaard Synthesis | 23-Aug-2005 | 0000000000 | Industrial Chemicals | 000000 00 |
Seqens North America FAQs
-
When was Seqens North America founded?
Seqens North America was founded in 1995.
-
Where is Seqens North America headquartered?
Seqens North America is headquartered in Newburyport, MA.
-
What is the size of Seqens North America?
Seqens North America has 150 total employees.
-
What industry is Seqens North America in?
Seqens North America’s primary industry is Multi-line Chemicals.
-
Is Seqens North America a private or public company?
Seqens North America is a Private company.
-
What is Seqens North America’s current revenue?
The current revenue for Seqens North America is 000000.
-
How much funding has Seqens North America raised over time?
Seqens North America has raised $15.7M.
-
Who are Seqens North America’s competitors?
Bayer, Par Pharmaceutical Companies, Dalton Pharma Services, CordenPharma, and Mallinckrodt are some of the 9 competitors of Seqens North America.
-
When was Seqens North America acquired?
Seqens North America was acquired on 28-Jun-2018.
-
Who acquired Seqens North America?
Seqens North America was acquired by Seqens.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
